Cartesian Therapeutics RNAC
NASDAQ RNAC
$7.36 +0.14 (+1.94%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cartesian Therapeutics (RNAC) Price to Earnings (2022)

Updated

Cartesian Therapeutics' (RNAC) Price to Earnings stood at 146.64 in Q4 2022, down 18.7% from the prior quarter.

Analysis

Cartesian Therapeutics (RNAC) Price to Earnings (2022) Analysis & Trends

Starting with Q1 2022, Cartesian Therapeutics' Price to Earnings history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at 180.44 (Q3 2022), 189.18 (Q2 2022) and 165.76 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Cartesian Therapeutics 216.87 Mn 216.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 146.64
Sep 30, 2022 180.44
Jun 30, 2022 189.18
Mar 31, 2022 165.76
API Access

Cartesian Therapeutics Price to Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-earnings&ticker=RNAC&period=max&api_key=YOUR_API_KEY